Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).


Malik Z., di Lorenzo G., Bracarda S., Ardavanis A., Basaran M. , Parente P., ...Daha Fazla

Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32 identifier